Literature DB >> 19275706

Drug targets in infections with Ebola and Marburg viruses.

Olinger G Gene1, Biggins E Julia, Melanson R Vanessa, Wahl-Jensen Victoria, Geisbert W Thomas, Hensley E Lisa.   

Abstract

The development of antiviral drugs for Ebola and Marburg viruses has been slow. To date, beyond supportive care, no effective treatments, prophylactic measures, therapies, or vaccines are approved to treat or prevent filovirus infections. In this review, we examine the current treatments available to administer care for filovirus infection, the potential therapeutic targets that can be used for filovirus drug development, and the various drug targeting techniques used against filoviruses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275706     DOI: 10.2174/187152609787847730

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  10 in total

1.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

Review 2.  Animal Models of Ebolavirus Infection.

Authors:  Marisa C St Claire; Dan R Ragland; Laura Bollinger; Peter B Jahrling
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

3.  Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.

Authors:  Adrián Lázaro-Frías; Sergio Gómez-Medina; Lucas Sánchez-Sampedro; Karl Ljungberg; Mart Ustav; Peter Liljeström; César Muñoz-Fontela; Mariano Esteban; Juan García-Arriaza
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

4.  Ebola virus disease: What clinicians in the United States need to know.

Authors:  William A Fischer; Timothy M Uyeki; Robert V Tauxe
Journal:  Am J Infect Control       Date:  2015-06-24       Impact factor: 2.918

5.  Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs.

Authors:  Elena Postnikova; Yu Cong; Lisa Evans DeWald; Julie Dyall; Shuiqing Yu; Brit J Hart; Huanying Zhou; Robin Gross; James Logue; Yingyun Cai; Nicole Deiuliis; Julia Michelotti; Anna N Honko; Richard S Bennett; Michael R Holbrook; Gene G Olinger; Lisa E Hensley; Peter B Jahrling
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

6.  MolData, a molecular benchmark for disease and target based machine learning.

Authors:  Arash Keshavarzi Arshadi; Milad Salem; Arash Firouzbakht; Jiann Shiun Yuan
Journal:  J Cheminform       Date:  2022-03-07       Impact factor: 5.514

Review 7.  Potential vaccines and post-exposure treatments for filovirus infections.

Authors:  Brian M Friedrich; John C Trefry; Julia E Biggins; Lisa E Hensley; Anna N Honko; Darci R Smith; Gene G Olinger
Journal:  Viruses       Date:  2012-09-21       Impact factor: 5.048

8.  Repurposed therapeutic agents targeting the Ebola virus: a protocol for a systematic review.

Authors:  Hussein Sweiti; Obinna Ekwunife; Thomas Jaschinski; Stefan K Lhachimi
Journal:  Syst Rev       Date:  2015-11-25

9.  Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus.

Authors:  V Karthick; N Nagasundaram; C George Priya Doss; Chiranjib Chakraborty; R Siva; Aiping Lu; Ge Zhang; Hailong Zhu
Journal:  Infect Dis Poverty       Date:  2016-02-17       Impact factor: 4.520

10.  Repurposed Therapeutic Agents Targeting the Ebola Virus: A Systematic Review.

Authors:  Hussein Sweiti; Obinna Ekwunife; Thomas Jaschinski; Stefan K Lhachimi
Journal:  Curr Ther Res Clin Exp       Date:  2017-02-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.